Tango Therapeutics, Inc. (TNGX)

Market Cap	173.51M
Revenue (ttm)	42.07M
Net Income (ttm)	-130.30M
Shares Out	108.11M
EPS (ttm)	-1.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,234,444
Open	1.520
Previous Close	1.540
Day's Range	1.520 - 1.655
52-Week Range	1.480 - 12.020
Beta	0.87
Analysts	Strong Buy
Price Target	12.33 (+668.22%)
Earnings Date	May 7, 2025

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: TNGX
• Website: https://www.tangotx.com

Financial Performance

In 2024, Tango Therapeutics's revenue was $42.07 million, an increase of 15.17% compared to the previous year's $36.53 million. Losses were -$130.30 million, 28.1% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price forecast is $12.33, which is an increase of 668.22% from the latest price.

Price Target

$12.33

(668.22% upside)

Analyst Consensus: Strong Buy